Phase Ii Trial Of Monoamine Oxidase Inhibitor Phenelzine In Biochemical Recurrent Prostate Cancer

Phenelzine demonstrated efficacy in patients with biochemical recurrent castrate-sensitive prostate cancer. Most treatment-related toxicities were mild, but rare significant and reversible cardiovascular toxicities were observed. Therapies directed at MAOA may represent a new avenue for treatment in patients with recurrent prostate cancer.